The Medicines Patent Pool (MPP) signed a licensing agreement with Pfizer in October 2019 to facilitate the clinical development of sutezolid, an investigational medicine for the treatment of tuberculosis (TB). Pfizer is granting MPP a non-exclusive, worldwide and royalty-free licence allowing potential future MPP sublicensees to access Pfizer’s preclinical, phase I and phase IIa clinical study data and results with the aim to further study, develop and make available this potential important component of new TB regimens.

MPP had already signed a licence with Johns Hopkins University in 2017 covering sutezolid in combination therapy, which did not include preclinical and clinical study data. This added element provided by the Pfizer-MPP licence can facilitate faster development of sutezolid.

Organisations interested in signing a sublicence with us are invited to click here for more information.


Click the logo to access the sublicensing agreement: